

Influenza H5N1 Vaccines Are Coming. Dr. William Makis

Part II

By [Dr. William Makis](#) and [Helen Branswell](#)

Theme: [Science and Medicine](#)

Global Research, May 02, 2024

[COVID Intel](#)

All Global Research articles can be read in 51 languages by activating the Translate Website button below the author's name (only available in desktop version).

To receive Global Research's Daily Newsletter (selected articles), [click here](#).

Click the share button above to email/forward this article to your friends and colleagues. Follow us on [Instagram](#) and [Twitter](#) and subscribe to our [Telegram Channel](#). Feel free to repost and share widely Global Research articles.

[Global Research Wants to Hear From You!](#)

Below is an excerpt from an article by [Helen Branswell](#) titled "Massive amounts of H5N1 vaccine would be needed if there's a bird flu pandemic. Can we make enough?":

"But with a brand-new flu virus — and H5N1 definitely falls into that category for humans — **everyone will be naive**. So the assumption of pandemic planners is that everyone would need two doses of vaccine in the first season of vaccinating against H5N1. (During the 2009 H1N1 pandemic, the new virus was distantly related to one that had circulated for much of the previous century, and one dose was adequate for protection. There's no expectation that would be true with an H5 pandemic.)"

"That math is daunting: The 8.1 billion people worldwide times two is **16.2 billion doses**. Babies under the age of 6 months aren't vaccinated against flu — their immune systems aren't yet sufficiently developed for it to be effective — so that number would be a bit lower. But there's always waste in vaccine delivery, so the **16 billion probably isn't far off.**"


"Moderna is currently testing an H5N1 vaccine, from the 2.3.4.4b subset of viruses, in people. [That trial](#) began last summer."

But the trial's listing in the Clinicaltrials.gov database is cagey about the dosages Moderna is testing, calling them simply dose number 1, 2 and 3.

"regulators will want more data before they embrace mRNA vaccines as a solution in a flu pandemic — though he and others have noted that in a true

crisis, “all bets are off.”

“I think if we make the proper investments, **we could very soon get to the point where we know what the dose needs to be and have mRNA vaccines against avian strains as part of our arsenal and scale it quickly.**”



[Click here to watch the video](#)

*

Note to readers: Please click the share button above. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

Dr. William Makis is a Canadian physician with expertise in Radiology, Oncology and Immunology. Governor General’s Medal, University of Toronto Scholar. Author of 100+ peer-reviewed medical publications.

Featured image: Colorized transmission electron micrograph of Avian influenza A H5N1 viruses (seen in gold) grown in MDCK cells (seen in green). (From the Public Domain)

The original source of this article is [COVID Intel](#)

Copyright © [Dr. William Makis](#) and [Helen Branswell](#), [COVID Intel](#), 2024

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: **Dr. William Makis** and **Helen Branswell**

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca